Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Update entities : Sellas life sciences group, inc. save search
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
| Email alert
Add to watchlist
life year update sciences financial results
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: 1.92%
H: 2.83%
C: 0.0%
sls009 positive update topline aml study
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: 6.67%
H: 0.89%
C: -6.25%
life update sciences
SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
Published: 2023-12-13 (Crawled : 13:30) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: 0.98%
H: 4.85%
C: 2.91%
update
SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-09 (Crawled : 00:00) - biospace.com/
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: 0.87%
H: 0.0%
C: -4.21%
business update financial results
SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia
Published: 2023-10-12 (Crawled : 20:00) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: 12.56%
H: 11.57%
C: 7.44%
life update sciences leukemia trial
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
Published: 2023-08-10 (Crawled : 20:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.39%
H: 0.33%
C: -0.49%
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: -0.64%
H: 3.85%
C: -0.72%
business life update sciences financial results
SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
Published: 2023-05-11 (Crawled : 20:00) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: -0.58%
H: 0.0%
C: -10.59%
business life update sciences financial results
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
Published: 2023-03-16 (Crawled : 21:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: -1.19%
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: -0.72%
H: 0.73%
C: -1.46%
business life year update sciences financial results
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
Published: 2022-11-14 (Crawled : 13:00) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: -31.65%
H: 2.89%
C: -18.01%
sciences life financial update results
SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
Published: 2022-11-14 (Crawled : 13:00) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: -31.65%
H: 2.89%
C: -18.01%
sciences life leukemia trial update acute myeloid leukemia
SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
Published: 2022-11-02 (Crawled : 13:00) - biospace.com/
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: -1.46%
H: 2.11%
C: -15.82%
sciences life update study
SELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022
Published: 2022-10-17 (Crawled : 13:00) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: 3.66%
H: 1.64%
C: 1.01%
sciences life update study
SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial
Published: 2022-06-27 (Crawled : 14:00) - biospace.com/
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: 1.69%
H: 0.0%
C: -3.33%
gfh009 ongoing sciences life trial update phase 1
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.